Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms
Open Access
- 1 June 2021
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8), bvab102
- https://doi.org/10.1210/jendso/bvab102
Abstract
Thyroid cancer is the most common endocrine malignancy, and the global incidence has increased rapidly over the past few decades. Anaplastic thyroid cancer (ATC) is highly aggressive, dedifferentiated, and patients have a median survival of fewer than 6 months. Oncogenic alterations in ATC include aberrant phosphoinositide 3 kinase (PI3K) signaling through receptor tyrosine kinase (RTK) amplification, loss of phosphoinositide phosphatase expression and function, and protein kinase B (Akt) amplification. Furthermore, the loss of expression of the tumor suppressor thyroid hormone receptor beta (TRβ) is strongly associated with ATC. TRβ is known to suppress PI3K in follicular thyroid cancer and breast cancer by binding to the PI3K regulatory subunit p85α. However, the role of TRβ in suppressing PI3K signaling in ATC is not completely delineated. Here we report that TRβ indeed suppresses PI3K signaling in ATC cell lines through unreported genomic mechanisms, including a decrease in RTK expression and an increase in phosphoinositide and Akt phosphatase expression. Furthermore, the reintroduction and activation of TRβ in ATC cell lines enables an increase in the efficacy of the competitive PI3K inhibitors LY294002 and buparlisib on cell viability, migration, and suppression of PI3K signaling. These findings not only uncover additional tumor suppressor mechanisms of TRβ but shed light on the implication of TRβ status and activation on inhibitor efficacy in ATC tumors.Funding Information
- National Cancer Institute (P30CA046934, 1F99CA245796-01)
- National Institutes of Health (U54 GM115516)
- UVM Cancer Center-Lake Champlain Cancer Research Organization (12577-21)
- UVM Larner College of Medicine
This publication has 52 references indexed in Scilit:
- Inhibition of Tumorigenesis by the Thyroid Hormone Receptor β in Xenograft ModelsThyroid®, 2014
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeuticsJournal of Hematology & Oncology, 2013
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid CarcinomasCancer Discovery, 2013
- Molecular pathogenesis and mechanisms of thyroid cancerNature Reviews Cancer, 2013
- Suppression of survival signalling pathways by the phosphatase PHLPPThe FEBS Journal, 2012
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2011
- mTOR signaling at a glanceJournal of Cell Science, 2009
- Thyroid Hormone Receptor β1 Acts as a Potent Suppressor of Tumor Invasiveness and MetastasisCancer Research, 2009
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Rapid nongenomic actions of thyroid hormoneProceedings of the National Academy of Sciences of the United States of America, 2006